Therapeutic effect of a calcium antagonist, efonidipine hydrochloride, on proteinuria in spontaneously hypertensive rats (SUR)

• Published in: Japanese Journal of Pharmacology Vol. 67; no. suppl.2; p. 317
• Main Authors: Shudo, Chlzuru, Sugita, Haruumi, Masuda, Yukinori, Tamura, Toru, Furukawa, Satoshi, llayashi, Ken-ichi, Mirata, Hiroaki, Shikada, Ken-lchl, Tanaka, Sakuya
• Format: Journal Article
• Language: English; Japanese
• Published: The Japanese Pharmacological Society 1995
• ISSN: 0021-5198; 1347-3506
• DOI: 10.1016/S0021-5198(19)47233-8

We reported previously that efonidipine hydrochloride (NZ-105) prevented a progression of proteinuria in SHR (Gen. Pharmac, in press). In this study, we designed to investigate whether NZ-105 improved the proteinuria in aged SHR (36 weeks old). NZ-105 (5 and 20 mg/kg; NZ-5 and NZ-20), nicardipine (20 mg/kg; NC) and captopril (30 mg/kg; CAP) were orally administered once a day for 4 weeks. The increase in urinary protein excretion (Upro) was significantly reduced by NZ-20 and CAP treatment. The Upro in NZ-5 and NC maintained the same level as before administration. Urine volume was increased by NZ-105 and NC, but that was decreased by CAP. The creatinine clearance (Ccr) was not significantly changed by NZ-105, but that in CAP reduced to about one half that in control. At autopsy, the histological changes in kidney were significantly suppressed in CAP, but only slightly in NZ-20. These results suggest that NZ-105 may have not only protective effect but also the therapeutic effect on proteinuria in SHR and it may be a beneficial point as an antihypertensive agent.